Future Market Insights, a leading market research firm, has recently released a comprehensive study forecasting a significant surge in the Global Chronic Pulmonary Hypertension Treatment Industry. The market, currently valued at US$ 7 billion in 2023, is expected to witness a robust CAGR of 5%, reaching a remarkable US$ 11.4 billion by the year 2033.
The research highlights the escalating prevalence of pulmonary hypertension and the growing accessibility to effective treatment options as key drivers propelling the market’s exponential growth over the next decade. The Chronic Pulmonary Hypertension Treatment Market is poised to become a crucial player in the healthcare landscape, providing innovative solutions for those affected by this disorder.
Request a Sample Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16779
The increasing incidence of the disease is one of the primary drivers of the chronic pulmonary hypertension therapy industry. According to the Pulmonary Hypertension Association, pulmonary hypertension affects 10-15% of patients with chronic obstructive pulmonary disease (COPD) and 30-40% of individuals with idiopathic pulmonary fibrosis (IPF). Pulmonary hypertension is also more common in persons with connective tissue illnesses such as scleroderma and lupus.
The availability of effective treatment choices is another factor driving the growth of the Chronic Pulmonary Hypertension Treatment market. Several medications, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, have been approved by regulatory authorities for the treatment of pulmonary hypertension. These drugs act by dilating the blood arteries in the lungs, lowering pulmonary artery pressure, and increasing blood flow.
Furthermore, rising pulmonary hypertension awareness among healthcare professionals and patients is expected to drive demand for effective treatment options. Pulmonary hypertension is frequently misdiagnosed or underdiagnosed, therefore raising awareness of the disease can help patients obtain timely and effective treatment.
Key Takeaways from the Global Chronic Pulmonary Hypertension Treatment Industry Study
- From 2018 to 2022, the Chronic Pulmonary Hypertension Treatment market grew at a CAGR of 3.5%.
- The global Chronic Pulmonary Hypertension Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
- As of 2033, the Chronic Pulmonary Hypertension Treatment Market is expected to reach US$ 11.4 Billion.
- According to the FMI analysis, the oral route of administration accounts for the largest market share.
- North America is expected to possess 40% market share for the Chronic Pulmonary Hypertension Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Chronic Pulmonary Hypertension Treatment,” says an FMI analyst
Ask Us Your Questions About This Report
https://www.futuremarketinsights.com/request-discount/rep-gb-16779
Global Chronic Pulmonary Hypertension Treatment Industry Competition
Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.
- In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension,” is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Chronic Pulmonary Hypertension Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on drug type, distribution channel, route of administration & region.
Request Report Customization@
https://www.futuremarketinsights.com/customization-available/rep-gb-16779
Key Segments Profiled in the Global Chronic Pulmonary Hypertension Treatment Industry Survey
By Drug Type:
- Endothelin Receptor Antagonists
- PDE-5 Inhibitors
- Prostacyclin Analogs
- SGC Stimulators
By Route of Administration:
- Oral
- Intravenous/Subcutaneous
- Inhalational
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube